Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Rotavirus Prophylaxis Market?
The market size of rotavirus prophylaxis has seen a robust increase in recent years. It is projected to rise from $9.05 billion in 2024 to $9.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.8%. The remarkable growth seen in the historic period can be credited to factors such as availability and fairness of vaccine distribution, the emergence of new rotavirus strains, research and development investments, and public health readiness.
The market size for rotavirus prophylaxis is predicted to experience robust growth in the coming few years. The market is projected to escalate to $14.45 billion by 2029, advancing at a compound annual growth rate (CAGR) of 9.8%. The growth anticipated in the forecast period can be linked to a rise in gastrointestinal disease burden, international expansion, vaccination initiatives, and vaccine reliability. Significant trends expected in the forecast period encompass next-generation vaccines, composite vaccines, improvements in vaccine delivery, and worldwide immunization cooperation.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
Which Growth Drivers Are Shaping The Rotavirus Prophylaxis Market Outlook?
The expansion of the rotavirus prophylaxis market is anticipated to be fuelled by the rising production of vaccine courses. A vaccine course, which is a designated dose intended to immunize an individual against a particular disease, boosts the immune response, enhancing resistance against rotavirus infection. This amplified immunity lessens disease susceptibly and augments the overall effectiveness of the vaccine. For example, a report by the United Nations International Children’s Emergency Fund (UNICEF), a US organization offering humanitarian and development support to children, stated in January 2022 that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were manufactured in 2022, with projected growth to 9.31 million courses by 2028. Additionally, around 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with a projected increase to 6.13 million courses by 2028. Hence, the growing vaccine production is set to propel the rotavirus prophylaxis market.
What Are The Primary Segmentation Parameters In The Rotavirus Prophylaxis Market?
The rotavirus prophylaxismarket covered in this report is segmented –
1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Rotarix: Single Dose; Multi-Dose
2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation
3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation
4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions
5) By Other Treatments: Supportive Care; Antidiarrheal Medications
How Are Market Trends Influencing Competition In The Rotavirus Prophylaxis Market?
Leading organizations in the rotavirus prophylaxis market are currently in the process of creating vaccines tailored to customer needs. The approval procedure for such vaccines is stringent, involving various stages of development and testing. This process is critical to ensure that the vaccines are safe and efficient in preventing this viral disease, especially among infants and young children. For instance, the UK-based pharmaceutical and biotech company GlaxoSmithKline PLC announced in November 2022 that the Food and Drug Administration (FDA) had granted approval for an oral-dosing applicator-only (liquid formulation) presentation of ROTARIX (Rotavirus Vaccine, Live and Oral), designed to prevent rotavirus gastroenteritis prompted by G1 and non-G1 types (G3, G4 and G9) in infants. The innovative oral-dosing applicator presentation is entirely liquid and does not require reconstitution before usage. The lyophilized and liquid formulations of ROTARIX are given orally in a two-dose series, contain the identical live, human-attenuated rotavirus strain, and are produced using similar methods.
Which Organizations Are At The Forefront Of The Rotavirus Prophylaxis Market?
Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
Which Region Holds The Greatest Opportunity For Rotavirus Prophylaxis Market Expansion?
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp
Browse Through More Reports Similar to the Global Rotavirus Prophylaxis Market 2025, By The Business Research Company
Cancer Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report
Dtp Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report
Companion Animal Veterinary Vaccines Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
